Who
M. Scot Roberts
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Altimmune.
In numbers
- Trades disclosed
- 112
- Buys
- 1
- Sells
- 4
- Bought
- $1,985
- Sold
- $960K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 4 May 2017
- Last trade
- 31 Jul 2026
- Last filed
- 3 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Jul 2026filed 3 Aug 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code A | $2,112875 at $2.41 | filing |
| 31 Jul 2026filed 3 Aug 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code A | $2,109875 at $2.41 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —222,670 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,430 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —222,670 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,430 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,775 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code M | —7,775 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code F | $13K2,329 at $5.55 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,775 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code M | —7,775 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code F | $13K2,329 at $5.55 | filing |
| 31 Jan 2026filed 3 Feb 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code A | $17K5,567 at $3.07 | filing |
| 31 Jan 2026filed 3 Feb 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code A | $17K5,567 at $3.07 | filing |
| 30 Jan 2026filed 3 Feb 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code M | —9,275 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code F | $16K2,859 at $5.60 | filing |
| 30 Jan 2026filed 3 Feb 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,275 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,275 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code M | —9,275 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code F | $16K2,859 at $5.60 | filing |
News
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026ALT · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name M. Scot Roberts; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.